An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia-Reference-Cited by-同舟云学术

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia

Published:2023-02-08 Issue:4 Volume:12 Page:
ISSN:2049-3614
Container-title:Endocrine Connections
language:
Short-container-title:

Author:

van’t Westeinde Annelies¹^ORCID,Karlsson Leif¹,Messina Valeria¹,Wallensteen Lena¹,Brösamle Manuela²,Dal Maso Giorgio³,Lazzerini Alessandro⁴,Kristensen Jette⁵,Kwast Diana⁶,Tschaidse Lea⁷,Auer Matthias K⁷,Nowotny Hanna F⁷,Persani Luca⁸⁹^ORCID,Reisch Nicole⁷^ORCID,Lajic Svetlana¹^ORCID

Affiliation:

1. Department of Women’s and Children’s Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden

2. European Patient Advocacy Group for Adrenal Diseases, European Reference Network on Rare Endocrine Conditions (Endo ERN), Endo ERN Coordinating Centre, Leiden, The Netherlands

3. ArfSAG (Associazione Refionale Famiglie Sindrome Adreno Genitale) c/o Unita Operativa di Pediatria, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsala-Malpighi, Bologna, Italy

4. Spanish Association of Congenital Adrenal Hyperplasia (CAH), Spain

5. ePAG & Chair of Danish Addison Patient Association, Aarhus, Denmark

6. Dutch Adrenal Society NVACP, Nijkerk, The Netherlands

7. Department of Endocrinology, Medizinische Klinik IV, Klinikum der Universität München, Munich, Germany

8. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

9. Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy

Abstract

First-trimester prenatal treatment with glucocorticoid (GC) dexamethasone (DEX) in pregnancies at risk for classic congenital adrenal hyperplasia (CAH) is associated with ethical dilemmas. Though effective in reducing virilisation in girls with CAH, it entails exposure to high doses of GC in fetuses that do not benefit from the treatment. The current paper provides an update on the literature on outcomes of prenatal DEX treatment in CAH cases and unaffected subjects. Long-term follow-up research is still needed to determine treatment safety. In addition, advances in early prenatal diagnostics for CAH and sex-typing as well as studies assessing dosing effects of DEX may avoid unnecessary treatment and improve treatment safety.

Publisher

Bioscientifica

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://ec.bioscientifica.com/downloadpdf/journals/ec/12/4/EC-22-0400.xml

Reference112 articles.

1. High frequency of nonclassical steroid 21-hydroxylase deficiency;Speiser,1985

2. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency;White,2000

3. Molecular genetics of 21-hydroxylase deficiency;Wedell,2011

4. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management;Claahsen-van der Grinten,2022

5. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline;Speiser,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward depathologizing queerness: An analysis of queer oppression in clinical genetics;Journal of Genetic Counseling;2023-10-25